- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
The Growth of Telehealth During COVID-19 and Its Future After: Dr Patricia Salber Interviews Dr Joseph Kvedar
Telehealth has been around for years in the United States, but it was not until the coronavirus disease 2019 (COVID-19) pandemic that it became so widely used.
Telehealth has been around for years in the United States, but it was not until the coronavirus disease 2019 (COVID-19) pandemic that it became regularly used. The growth of telehealth was fueled by the inability to see patients in person at the beginning of the pandemic and a move by the government to temporarily relax regulations.
Joseph Kvedar, MD, president of the American Telemedicine Association, professor of Dermatology at Harvard Medical School, co-chair of the American Medical Association's Digital Medicine Payment Advisory Group, and editor-in-chief of npj Digital Medicine, explained that some of those relaxations might continue on after the COVID-19 pandemic passes, but some may get rolled back.
In conversation with Patricia Salber, MD, MBA, of The Doctor Weighs In, Kvedar also discussed how breakthroughs in technology have helped make virtual visits possible, the future of telehealth, and more.
Listen above or through one of these podcast services:
Learn more:
Contributor: Telehealth Claim Lines Increased 4132% Nationally From June 2019 to June 2020
Continuation of Routine Screenings, Care Is Crucial During COVID-19 Pandemic
ACR Position Statement Supports Use of Telemedicine After COVID-19 Crisis
Which Telehealth Changes Will Become Permanent? Hints May Come Next Month
In-person Visits Are Invaluable, but Telehealth Is Here to Stay
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
